ArticleFrontiers in immunology2026
Integrating multi-omics data reveals IL-8 positive cancer-associated fibroblasts as mediators of chemotherapy-induced tumor progression in breast cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent studies have shown that while chemotherapy kills tumor cells, it may also induce adaptive changes in cells within the tumor microenvironment, particularly cancer-associated fibroblasts (CAFs), which could paradoxically promote tumor progression. This study aimed to investigate the role of CAFs exposed to paclitaxel (PTX) or doxorubicin (DOX) in tumor progression and explore the underlying mechanisms. Methods: We examined the effects of PTX- or DOX-exposed CAFs on tumor migration and invasion through Results: Our findings showed that CAFs exposed to PTX or DOX further promoted tumor migration and invasion compared to untreated CAFs. Notably, PTX and DOX significantly increased IL-8 expression levels in CAFs, suggesting that IL-8 may be a key cytokine mediating the tumor-promoting effect of CAFs exposed to chemotherapeutic agents. Interestingly, this tumor-promoting effect could be partly reversed by reparixin, an IL-8 receptor inhibitor. Mendelian randomization analysis confirmed that both IL-8 eQTL and plasma IL-8 levels were significantly associated with breast cancer risk. Further insights from BayesPrism and scPagwas indicated that IL-8 + CAFs were associated with clinical prognosis and may play a critical role in breast cancer progression. Furthermore, we confirmed the tumor-promoting effect of CAFs-derived IL-8. Mechanistically, IL-8 may modulate apoptosis by activating the NF-κB pathway, thereby inhibiting tumor cell apoptosis and leading to chemoresistance. Clinically, high IL-8 expression correlated with chemoresistance and poor survival in breast cancer patients. Conclusion: Our study suggests that the upregulation of IL-8 in CAFs following PTX or DOX treatment may contribute to chemotherapy-mediated tumor progression. These findings provide potential avenues for improving chemotherapy outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.